Song Li Pharmaceutical - B: The US clinical study of ASC47 combined with Simeglutide for the treatment of obesity has completed dosing for all subjects.

Galile Pharmaceutical announced that a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and preliminary efficacy of a single dose of the ultra-long-acting subcutaneous injection ASC47 combined with semaglutide in obese subjects without type 2 diabetes has recently been completed in all 28 participants. ASC47 is a thyroid hormone receptor beta selective small molecule agonist developed independently by Galile, targeting fat tissue with ultra-long-acting subcutaneous injection. ASC47 has unique differentiation characteristics, targeting fat tissue to produce dose-dependent high drug concentrations in fat tissue. In a diet-induced obese mouse model, ASC47 with high drug concentrations in fat tissue reduced more fat compared to semaglutide and liraglutide, with significant differences. ASC47 monotherapy in Phase Ib obese subject studies showed a half-life of up to 40 days. In a head-to-head comparison in DIO mouse models, low-dose ASC47 in combination with semaglutide reduced weight by 56.7% more than semaglutide monotherapy, without reducing muscle. Top-line data is expected to be obtained in the fourth quarter of 2025.